Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers

Jongdoo Lim, Su Tang Lo, Sonia Hill, Giovanni M. Pavan, Xiankai Sun, Eric E. Simanek

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The antitumor activities of triazine dendrimers bearing paclitaxel, a well-known mitotic inhibitor, are evaluated in SCID mice bearing human prostate cancer xenografts. To increase the activity of a first generation prodrug 1 that contained twelve paclitaxel molecules tethered via an ester linkage, the new construct described here, prodrug 2, tethers paclitaxel with linkers containing both an ester and disulfide. While PEGylation is necessary for solubility, and may improve biocompatibility and increase plasma half-life, it increases the heterogeneity of the sample with an average of eight to nine PEG chains (2 kDa each) incorporated. The heterogeneous population of PEGylated materials was used without fractionation based on models obtained from molecular dynamics simulations. Three models were examined; hexaPEGylated, nonaPEGylated, and dodecaPEGylated constructs. Intravenous delivery of prodrug 2 was performed by single, double or triple dosing regimes with doses spaced by one week. The doses varied from 50 mg of paclitaxel/kg to 200 mg of paclitaxel/kg. Tumor growth arrest and regression was observed over the 10-week treatment period without mortality for mice treated with the 50 mg of paclitaxel/kg treated three times.

Original languageEnglish (US)
Pages (from-to)404-412
Number of pages9
JournalMolecular Pharmaceutics
Volume9
Issue number3
DOIs
StatePublished - Mar 5 2012

Fingerprint

Dendrimers
Triazines
Molecular Dynamics Simulation
Paclitaxel
Prodrugs
Esters
SCID Mice
Heterografts
Disulfides
Solubility
Half-Life
Prostatic Neoplasms
Mortality
Growth
Population
Neoplasms

Keywords

  • dendrimer
  • drug delivery
  • molecular dynamics
  • paclitaxel
  • prostate cancer
  • simulation
  • triazine
  • xenografts

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers. / Lim, Jongdoo; Lo, Su Tang; Hill, Sonia; Pavan, Giovanni M.; Sun, Xiankai; Simanek, Eric E.

In: Molecular Pharmaceutics, Vol. 9, No. 3, 05.03.2012, p. 404-412.

Research output: Contribution to journalArticle

Lim, Jongdoo ; Lo, Su Tang ; Hill, Sonia ; Pavan, Giovanni M. ; Sun, Xiankai ; Simanek, Eric E. / Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers. In: Molecular Pharmaceutics. 2012 ; Vol. 9, No. 3. pp. 404-412.
@article{e61b5ebb4dd841b7926c63e31f08a4e7,
title = "Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers",
abstract = "The antitumor activities of triazine dendrimers bearing paclitaxel, a well-known mitotic inhibitor, are evaluated in SCID mice bearing human prostate cancer xenografts. To increase the activity of a first generation prodrug 1 that contained twelve paclitaxel molecules tethered via an ester linkage, the new construct described here, prodrug 2, tethers paclitaxel with linkers containing both an ester and disulfide. While PEGylation is necessary for solubility, and may improve biocompatibility and increase plasma half-life, it increases the heterogeneity of the sample with an average of eight to nine PEG chains (2 kDa each) incorporated. The heterogeneous population of PEGylated materials was used without fractionation based on models obtained from molecular dynamics simulations. Three models were examined; hexaPEGylated, nonaPEGylated, and dodecaPEGylated constructs. Intravenous delivery of prodrug 2 was performed by single, double or triple dosing regimes with doses spaced by one week. The doses varied from 50 mg of paclitaxel/kg to 200 mg of paclitaxel/kg. Tumor growth arrest and regression was observed over the 10-week treatment period without mortality for mice treated with the 50 mg of paclitaxel/kg treated three times.",
keywords = "dendrimer, drug delivery, molecular dynamics, paclitaxel, prostate cancer, simulation, triazine, xenografts",
author = "Jongdoo Lim and Lo, {Su Tang} and Sonia Hill and Pavan, {Giovanni M.} and Xiankai Sun and Simanek, {Eric E.}",
year = "2012",
month = "3",
day = "5",
doi = "10.1021/mp2005017",
language = "English (US)",
volume = "9",
pages = "404--412",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers

AU - Lim, Jongdoo

AU - Lo, Su Tang

AU - Hill, Sonia

AU - Pavan, Giovanni M.

AU - Sun, Xiankai

AU - Simanek, Eric E.

PY - 2012/3/5

Y1 - 2012/3/5

N2 - The antitumor activities of triazine dendrimers bearing paclitaxel, a well-known mitotic inhibitor, are evaluated in SCID mice bearing human prostate cancer xenografts. To increase the activity of a first generation prodrug 1 that contained twelve paclitaxel molecules tethered via an ester linkage, the new construct described here, prodrug 2, tethers paclitaxel with linkers containing both an ester and disulfide. While PEGylation is necessary for solubility, and may improve biocompatibility and increase plasma half-life, it increases the heterogeneity of the sample with an average of eight to nine PEG chains (2 kDa each) incorporated. The heterogeneous population of PEGylated materials was used without fractionation based on models obtained from molecular dynamics simulations. Three models were examined; hexaPEGylated, nonaPEGylated, and dodecaPEGylated constructs. Intravenous delivery of prodrug 2 was performed by single, double or triple dosing regimes with doses spaced by one week. The doses varied from 50 mg of paclitaxel/kg to 200 mg of paclitaxel/kg. Tumor growth arrest and regression was observed over the 10-week treatment period without mortality for mice treated with the 50 mg of paclitaxel/kg treated three times.

AB - The antitumor activities of triazine dendrimers bearing paclitaxel, a well-known mitotic inhibitor, are evaluated in SCID mice bearing human prostate cancer xenografts. To increase the activity of a first generation prodrug 1 that contained twelve paclitaxel molecules tethered via an ester linkage, the new construct described here, prodrug 2, tethers paclitaxel with linkers containing both an ester and disulfide. While PEGylation is necessary for solubility, and may improve biocompatibility and increase plasma half-life, it increases the heterogeneity of the sample with an average of eight to nine PEG chains (2 kDa each) incorporated. The heterogeneous population of PEGylated materials was used without fractionation based on models obtained from molecular dynamics simulations. Three models were examined; hexaPEGylated, nonaPEGylated, and dodecaPEGylated constructs. Intravenous delivery of prodrug 2 was performed by single, double or triple dosing regimes with doses spaced by one week. The doses varied from 50 mg of paclitaxel/kg to 200 mg of paclitaxel/kg. Tumor growth arrest and regression was observed over the 10-week treatment period without mortality for mice treated with the 50 mg of paclitaxel/kg treated three times.

KW - dendrimer

KW - drug delivery

KW - molecular dynamics

KW - paclitaxel

KW - prostate cancer

KW - simulation

KW - triazine

KW - xenografts

UR - http://www.scopus.com/inward/record.url?scp=84863229418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863229418&partnerID=8YFLogxK

U2 - 10.1021/mp2005017

DO - 10.1021/mp2005017

M3 - Article

C2 - 22260328

AN - SCOPUS:84863229418

VL - 9

SP - 404

EP - 412

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 3

ER -